A lot to like re your Amarin outlook and what to look for with option activity. We started today with 2k shares AUPH, basis of $1.94. Only AMRN remains range-bound now.
Apples vs oranges AUPH was not that impressive IMHO until they released the data on severe LN I own a small position . My wife works with Nephrologist who treat LN patients and is the “ go to “ PA in dialysis clinics she rounds AMRN does not unfortunately have that catalyst … new data showing important clinical benefit Scripts ( both AMRN and the generics ) are stuck around 100k a week as per data Raf provides Why is that ? Can PFE do better ? Their trial run in Canada should answer that Otherwise it’s on to the EU Kiwi
News 
Market Data 
Discover 
AI
